Approval · Notice of Compliance 19563 · 2017
RYDAPT: Notice of Compliance 19563
Issued July 21, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19563
- Date
- July 21, 2017
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RYDAPT | 02466236 | Marketed |
Medicinal ingredients
- MIDOSTAURIN 25 MG per CAP